The development of new drug productions were discussed at the meeting of the RSPP
The Head of GEROPHARM Group Petr Rodionov took part in the joint meeting of the RSPP Commission on Health Industry, the RSPP Commission on Pharmaceutical and Medical Industry and the CCI Committee for Entrepreneurship in Healthcare and Medical Industry related to the development of drugs and medical products production. The event was held on April 18 in Moscow.
The Deputy Director of the Department of Pharmaceutical and Medical Industry of the Ministry of Industry and Trade D. Kolobov, the Deputy Director of the Contract System Development Department of the Ministry of Economic Development D. Gotovtsev, the Chairman of the RSPP Commission on the Pharmaceutical and Medical Industry Y. Kalinin, the Chairman of the RSPP Commission on Health Industry V. Cherepov and the Chairman of the CCI Committee for Entrepreneurship in Healthcare and Medical Industry V. Sergienko, as well as the representatives of the leading companies-manufacturers of drug products participated in the discussion.
The creation of full cycle productions in Russia was the most important topic for discussion. The Head of GEROPHARM Group Petr Rodionov stressed once again that today it is not reasonable to discuss the issues connected with the capacities necessary for the production of finished dosage forms of insulin, as there is a surplus of such products in Russia and they can not affect the current state of the industry. Therefore, speaking about full cycle insulin production, it is necessary to keep in mind the production of the substance.
Petr Rodionov also shared information about the terms of bringing new drug products to the market and the company's plans for the production capacities expansion, which will help the company to cover 100% of the Russian demand for genetically engineered and analogue insulins. He emphasized that for the further development of insulin production in Russia, the part of currently discussed support measures can be considered very effective, for example, preferences, depending on the depth of localization, and the mechanism of special investment contracts conclusion with the possibility of obtaining the status of a sole supplier. However, some initiatives, in particular, the procurement centralization at the Federal level carries significant risks, like supply disruptions, which for the patients with diabetics can be a matter of life and death.
Among the most important issues, mentioned by the Head of GEROPHARM, was the topic related to the violation of the legislation on public procurement - when the procurement is conducted by trademarks but not by INN, as it is prescribed in the Federal law 44 "On thecontract system". The existence of similar problems was also confirmed by other pharmaceutical manufacturers.
In conclusion, the participants agreed that today there are enough capacities for full cycle insulin production in Russia and there is a potential for providing the country with necessary drugs.The outcome of the meeting was the decision to support the projects, presented by the RSPP, and their consideration in the federal executive bodies.